Photo by nci from unsplash
Infusional alemtuzumab followed by consolidating allogeneic hematopoietic stem cell transplantation in eligible patients is considered a standard of care in T‐cell prolymphocytic leukemia (T‐PLL). Antibody selection against CD52 has been… Click to show full abstract
Infusional alemtuzumab followed by consolidating allogeneic hematopoietic stem cell transplantation in eligible patients is considered a standard of care in T‐cell prolymphocytic leukemia (T‐PLL). Antibody selection against CD52 has been associated with the development of CD52‐negative leukemic T cells at time of relapse. Clinical implications and molecular mechanisms underlying this phenotypic switch are unknown.
Keywords:
cd52;
cell prolymphocytic;
mutations piga;
prolymphocytic leukemia;
cell
Journal Title: European Journal of Haematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!